314.40

1.92% 5.92

Alnylam Pharmaceuticals Inc (ALNY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALNY? Forum Prognose

Schlusskurs vom Vortag:

$308.48

Offen:

$302.55

24-Stunden-Volumen:

1.39M

Relative Volume:

0.94

Marktkapitalisierung:

$41.54B

Einnahmen:

$3.21B

Nettoeinkommen (Verlust:

$43.57M

KGV:

1,307.28

EPS:

0.2405

Netto-Cashflow:

$221.36M

1W Leistung:

-4.19%

1M Leistung:

-15.02%

6M Leistung:

-27.31%

1J Leistung:

+18.69%

1-Tages-Spanne:

$302.55

$318.44

1-Wochen-Bereich:

$298.00

$329.92

52-Wochen-Spanne:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Firmenname

Alnylam Pharmaceuticals Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (622)

Telefon

(617) 551-8200

Adresse

675 WEST KENDALL STREET, CAMBRIDGE, MA

Mitarbeiter

2,230

Twitter

@alnylam

Nächster Verdiensttermin

2026-02-12

Neueste SEC-Einreichungen

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2026-01-07	Fortgesetzt	Oppenheimer	Outperform
2025-08-04	Hochstufung	Oppenheimer	Perform → Outperform
2025-08-04	Hochstufung	Wolfe Research	Underperform → Peer Perform
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2025-03-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-11-12	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-08-16	Hochstufung	Goldman	Neutral → Buy
2024-02-16	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-08	Eingeleitet	Wells Fargo	Equal Weight
2023-10-11	Herabstufung	Oppenheimer	Outperform → Perform
2023-09-29	Eingeleitet	Raymond James	Outperform
2023-05-05	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Eingeleitet	SMBC Nikko	Neutral
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Buy
2022-09-09	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-27	Herabstufung	Guggenheim	Buy → Neutral
2022-06-07	Eingeleitet	William Blair	Outperform
2022-04-25	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Eingeleitet	Citigroup	Buy
2022-02-03	Hochstufung	Guggenheim	Neutral → Buy
2022-01-03	Hochstufung	Piper Sandler	Neutral → Overweight
2021-11-22	Hochstufung	Goldman	Neutral → Buy
2021-11-22	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-04	Hochstufung	UBS	Neutral → Buy
2021-08-04	Herabstufung	Piper Sandler	Overweight → Neutral
2021-02-22	Herabstufung	Guggenheim	Buy → Neutral
2021-02-12	Herabstufung	Citigroup	Buy → Neutral
2021-02-12	Bestätigt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Fortgesetzt	Berenberg	Hold
2020-09-08	Eingeleitet	Citigroup	Buy
2020-08-11	Herabstufung	Oppenheimer	Outperform → Perform
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-05-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-24	Fortgesetzt	Evercore ISI	Outperform
2020-03-19	Eingeleitet	Berenberg	Buy
2019-12-19	Bestätigt	Chardan Capital Markets	Buy
2019-11-20	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-05-23	Fortgesetzt	Goldman	Neutral
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-06	Hochstufung	Evercore ISI	In-line → Outperform
2019-03-05	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Eingeleitet	UBS	Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-13	Bestätigt	Stifel	Buy
2018-08-07	Hochstufung	Stifel	Hold → Buy
2018-05-04	Bestätigt	Stifel	Hold
2018-03-28	Eingeleitet	Evercore ISI	In-line

Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

01:26 AM

Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Finviz

01:26 AM

Feb 13, 2026

Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback? - simplywall.st

Feb 13, 2026

Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations (ALNY) - Seeking Alpha

Feb 13, 2026

RBC Capital lowers Alnylam Pharmaceuticals stock price target on short-term headwinds - Investing.com Canada

Feb 13, 2026

ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down - TradingView

Feb 13, 2026

Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews - Benzinga

Feb 13, 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating - marketscreener.com

Feb 13, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital - MarketBeat

Feb 13, 2026

Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback - Yahoo Finance

Feb 13, 2026

Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) ROE Of 19% Impressive? - Yahoo Finance

Feb 13, 2026

Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 13, 2026

Alnylam turns a profit for first time in 24-year history - The Business Journals

Feb 12, 2026

Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q4 2025 Earnings Conference - 富途牛牛

Feb 12, 2026